

Filed September 16, 2025

On behalf of **Dr. Falk Pharma GmbH**

By: Nathanael R. Luman (Reg. No. 63,160)
Eric S. Furman (Reg. No. 45,664)
Phillip J. Minnick (Reg. No. 81,223)
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
Tel.: (949) 760-0404
Fax: (949) 760-9502
Email: BoxFalkPharma@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner,

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner.

Case IPR2025-00054
Patent No. 11,246,828

**PETITIONER'S OBJECTIONS TO ADMISSIBILITY OF PATENT
OWNER'S EVIDENCE**

Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner, Dr. Falk Pharma GmbH (“Dr. Falk”) hereby timely files its objections to the admissibility of evidence submitted with the Patent Owner Response filed by Ellodi Pharmaceuticals, L.P. (“Ellodi”) on September 9, 2025.

Exhibit Number and Description	Objections
EX2006 - Miehkle, Gut 0:1-10 (2015)	Relevance (FRE 401, 403): The date markings on this document are after the asserted priority date of Ellodi’s patent. Ellodi’s reliance on this document is misleading because the document does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi’s alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.
EX2007 - Declaration of M. C. Davies	Relevance, Misleading (FRE 106, 401, 402, 403): ¶¶ 48, 87, 90, 101, 106, 114, 137-139 are misleading, incomplete, and irrelevant because they lack support for the contentions for which they are cited and do not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi’s alleged invention. Improper Testimony by Expert Witness (FRE 702): ¶¶ 48, 87, 90, 101, 106, 114, 137-139 are not based on sufficient facts and data, and do not reliably apply facts and data using scientific principles.

Exhibit Number and Description	Objections
EX2010 – EoE FLUTE Clinical Trials Study, Apr. 26, 2023	Relevance (FRE 401, 403): The date markings on this document are after the asserted priority date of Ellodi’s patent. Ellodi’s reliance on this document is misleading because the document does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi’s alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.
EX2016 Hahm, Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations	Relevance (FRE 401, 403): The date markings on this document are absent. Ellodi’s reliance on this document is misleading because the document does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi’s alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.
EX2022 - Orange Book: N213976 (Eohilia™)	Relevance (FRE 401, 403): The date markings on this document are after the asserted priority date of Ellodi’s patent. Ellodi’s reliance on this document is misleading because the document does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi’s alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.

Exhibit Number and Description	Objections
EX2028 - U.S. Patent 9,867,780	Relevance (FRE 401, 403): The priority date for this patent is after the asserted priority date of Ellodi's patent. Ellodi's reliance on this patent is misleading because the patent does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi's alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.
EX2029 - Geoffrey Lee Report	Relevance, Misleading (FRE 106, 401, 402, 403): Ellodi's reliance on this document is misleading, incomplete, and irrelevant because it lacks support for the contentions for which it is cited and does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi's alleged invention. Improper Testimony by Expert Witness (FRE 702): The content of this document is not based on sufficient facts and data and does not reliably apply facts and data using scientific principles.
EX2030 - Jorveza® label	Relevance (FRE 401, 403): The date markings on this document are after the asserted priority date of Ellodi's patent. Ellodi's reliance on this document is misleading because the document does not represent the knowledge of a person of ordinary skill in the art at the time of Ellodi's alleged invention. Hearsay (FRE 802): The exhibit includes out-of-court statements offered for the truth of the matter asserted.

Respectfully submitted,

Dated: September 16, 2025

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP

Attorney for Petitioner Dr. Falk Pharma GmbH

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on the date below a copy of this
**PETITIONER'S OBJECTIONS TO ADMISSIBILITY OF PATENT
OWNER'S EVIDENCE** was served by email to counsel for Ellodi at addresses
below:

Sanya Sukduang
ssukduang@cooley.com

Jonathan Davies
jdavies@cooley.com

Jonathan Cousin
jcousin@cooley.com

Isha Agarwal
iagarwal@cooley.com

Ellodi_IPR@cooley.com

Dated: September 16, 2025

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)

KNOBBE MARTENS OLSON & BEAR, LLP